Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw9414. doi: 10.1126/scitranslmed.aaw9414.

PMID:
31554741
2.

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.

Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F.

Br J Haematol. 2019 May;185(4):670-678. doi: 10.1111/bjh.15814. Epub 2019 Feb 28.

PMID:
30820940
3.

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.

Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Müschen M, Ngo VN.

Blood. 2019 Jan 24;133(4):306-318. doi: 10.1182/blood-2018-05-851667. Epub 2018 Dec 10.

PMID:
30530749
4.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW.

Lancet Haematol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1.

PMID:
30389036
5.

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.

Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA.

J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.

6.

Targeting myeloid-derived suppressor cells for cancer immunotherapy.

Liu Y, Wei G, Cheng WA, Dong Z, Sun H, Lee VY, Cha SC, Smith DL, Kwak LW, Qin H.

Cancer Immunol Immunother. 2018 Aug;67(8):1181-1195. doi: 10.1007/s00262-018-2175-3. Epub 2018 May 31. Review.

PMID:
29855694
7.

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A.

Cancer. 2018 Jun 15;124(12):2561-2569. doi: 10.1002/cncr.31361. Epub 2018 May 3.

8.

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, Popescu M, Lee VY, Neelapu SS, Kwak LW.

BMC Cancer. 2018 Feb 13;18(1):187. doi: 10.1186/s12885-018-4094-2.

9.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R.

Ann Oncol. 2018 Mar 1;29(3):724-730. doi: 10.1093/annonc/mdx791.

10.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28.

11.

Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo.

Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, Smith DL, Wen F, Sun H, Kim K, Cha S, Bover L, Neelapu SS, Kwak LW.

Clin Cancer Res. 2018 Mar 1;24(5):1114-1123. doi: 10.1158/1078-0432.CCR-17-1193. Epub 2017 Nov 27.

12.

Absence of Grail promotes CD8+ T cell anti-tumour activity.

Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R.

Nat Commun. 2017 Aug 10;8(1):239. doi: 10.1038/s41467-017-00252-w.

13.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.

Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B.

Lancet Haematol. 2017 Aug;4(8):e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14.

PMID:
28712940
14.

IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay.

Weng J, Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang L, Yang J, Yi Q, Neelapu SS, Kwak LW.

Oncoimmunology. 2016 Oct 7;5(12):e1237327. doi: 10.1080/2162402X.2016.1237327. eCollection 2016.

15.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P.

J Clin Oncol. 2017 Jan;35(1):24-31. Epub 2016 Oct 24.

16.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

17.

Targeting B-cell malignancies through human B-cell receptor specific CD4+ T cells.

Weng J, Baio FE, Moriarty KE, Torikai H, Wang H, Liu Z, Maiti SN, Gwak D, Popescu MS, Cha SC, Cooper LJ, Neelapu SS, Kwak LW.

Oncoimmunology. 2016 Sep 19;5(11):e1232220. doi: 10.1080/2162402X.2016.1232220. eCollection 2016.

18.

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.

Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE.

Br J Haematol. 2016 Jan;172(1):80-8. doi: 10.1111/bjh.13796. Epub 2015 Dec 9.

19.

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J.

Oncotarget. 2015 Oct 27;6(33):34329-41. doi: 10.18632/oncotarget.6020.

20.

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.

Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA.

Br J Haematol. 2015 Dec;171(5):726-35. doi: 10.1111/bjh.13659. Epub 2015 Sep 11.

21.

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y.

Br J Haematol. 2015 Nov;171(4):509-16. doi: 10.1111/bjh.13628. Epub 2015 Aug 10.

PMID:
26260306
22.

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.

Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A.

Br J Haematol. 2015 Nov;171(4):463-70. doi: 10.1111/bjh.13603. Epub 2015 Jul 27.

23.

Targeting tumor-associated myeloid cells for cancer immunotherapy.

Qin H, Wei G, Gwak D, Dong Z, Xiong A, Kwak LW.

Oncoimmunology. 2015 Apr 2;4(3):e983961. eCollection 2015 Mar.

24.

Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.

Zhang M, He J, Liu Z, Lu Y, Zheng Y, Li H, Xu J, Liu H, Qian J, Orlowski RZ, Kwak LW, Yi Q, Yang J.

Oncotarget. 2015 Apr 20;6(11):8567-78.

25.

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW.

Br J Haematol. 2015 Jun;169(6):814-23. doi: 10.1111/bjh.13367. Epub 2015 Mar 31.

26.

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.

Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A.

Br J Haematol. 2015 Jun;169(5):689-93. doi: 10.1111/bjh.13349. Epub 2015 Mar 29.

27.

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA.

Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):152-8. doi: 10.1016/j.clml.2014.09.001. Epub 2014 Sep 28.

28.

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS.

Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.

29.

Rush hour traffic: directing T cells to tumor.

Neelapu SS, Kwak LW.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju301. doi: 10.1093/jnci/dju301. Print 2014 Nov. No abstract available.

PMID:
25255804
30.

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.

Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW.

Br J Haematol. 2014 Oct;167(2):207-13. doi: 10.1111/bjh.13021. Epub 2014 Jul 8.

PMID:
25040450
31.

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR.

Br J Haematol. 2014 Sep;166(6):891-901. doi: 10.1111/bjh.12982. Epub 2014 Jun 18.

PMID:
24943107
32.

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.

Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW.

Nat Med. 2014 Jun;20(6):676-81. doi: 10.1038/nm.3560. Epub 2014 May 25.

33.

FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, Kwak LW, Samaniego F.

Leukemia. 2014 Dec;28(12):2376-87. doi: 10.1038/leu.2014.126. Epub 2014 Apr 3.

34.

Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS.

Int J Cancer. 2014 Dec 15;135(12):2834-46. doi: 10.1002/ijc.28937. Epub 2014 May 12.

35.

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.

Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K.

Cancer Sci. 2014 Jul;105(7):795-801. doi: 10.1111/cas.12430. Epub 2014 Jun 3.

36.

The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.

Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW, Roy K.

Biomaterials. 2014 Jul;35(21):5491-504. doi: 10.1016/j.biomaterials.2014.03.039. Epub 2014 Apr 8.

37.

Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.

Baio FE, Kwak LW, Weng J.

Am J Blood Res. 2014 Dec 15;4(2):46-52. eCollection 2014. Review.

38.

Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.

Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, Zhong Y, Lu Y, Hong B, Zhang M, Lin P, Du J, Hou J, Qian J, Kwak LW, Yi Q, Yang J.

PLoS One. 2013 Dec 10;8(12):e82453. doi: 10.1371/journal.pone.0082453. eCollection 2013.

39.

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS.

Lancet Oncol. 2014 Jan;15(1):69-77. doi: 10.1016/S1470-2045(13)70551-5. Epub 2013 Dec 11.

40.

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.

Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L.

Br J Haematol. 2013 Dec;163(5):611-20. doi: 10.1111/bjh.12585. Epub 2013 Oct 1.

41.

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.

Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A.

Clin Cancer Res. 2013 Dec 15;19(24):6882-90. doi: 10.1158/1078-0432.CCR-13-1906. Epub 2013 Oct 4.

42.

Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.

Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ.

J Immunol. 2013 Oct 1;191(7):3641-50. doi: 10.4049/jimmunol.1202752. Epub 2013 Sep 6.

43.

In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.

Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M.

Mol Cancer Ther. 2013 Nov;12(11):2494-504. doi: 10.1158/1535-7163.MCT-13-0156. Epub 2013 Aug 29.

44.

Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.

Sakamaki I, Kwak LW, Cha SC, Yi Q, Lerman B, Chen J, Surapaneni S, Bateman S, Qin H.

Leukemia. 2014 Feb;28(2):329-37. doi: 10.1038/leu.2013.177. Epub 2013 Jun 14.

45.

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.

Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B.

Br J Haematol. 2013 Jul;162(1):138-41. doi: 10.1111/bjh.12326. Epub 2013 Apr 17. No abstract available.

PMID:
23590726
46.

Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen.

Cha SC, Qin H, Kannan S, Rawal S, Watkins LS, Baio FE, Wu W, Ong J, Wei J, Kwak B, Kim S, Popescu MS, Paick DS, Kim K, Luong A, Davis RE, Schroeder HW Jr, Kwak LW, Neelapu SS.

J Immunol. 2013 May 1;190(9):4887-98. doi: 10.4049/jimmunol.1300179. Epub 2013 Mar 27.

47.

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.

Wang L, Qian J, Lu Y, Li H, Bao H, He D, Liu Z, Zheng Y, He J, Li Y, Neelapu S, Yang J, Kwak LW, Yi Q, Cai Z.

Haematologica. 2013 Sep;98(9):1458-66. doi: 10.3324/haematol.2012.071340. Epub 2013 Mar 18.

48.

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):99-105. doi: 10.1016/j.clml.2012.11.002. Epub 2012 Dec 29.

49.

The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.

Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB Jr.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):15-8. doi: 10.1016/j.clml.2012.09.009. Epub 2012 Nov 6.

50.

p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.

He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J.

Cancer Res. 2012 Dec 15;72(24):6393-402. doi: 10.1158/0008-5472.CAN-12-2664. Epub 2012 Oct 11.

Supplemental Content

Support Center